SOLID ORAL COMPOSITIONS (MONOLITHIC ARRAYS) (Q4209181): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
SOLID ORAL COMPOSITIONS (MONOLITHIC ARRAYS) | |||||||||||||||
| Property / summary | |||||||||||||||
THIS INVENTION CONCERNS CONTROLLED-RELEASE SOLID ORAL COMPOSITIONS COMPRISING A CORE CONSISTING OF A MONOLITHIC MATRIX COMPRISING AT LEAST ONE LOW, MEDIUM, AL-TA VISCOSITY HYDROXYPROPYLMETHYLCELLULOSE, OR A MIXTURE THEREOF, ANHYDROUS DICALCIUM PHOSPHATE OR MONOHYDRATE, METILCELLULOSE, ONE OR MORE SUPERDISGREGANT POLYMERS AND AN OUTER COATING OF THAT CORE CONSISTING OF A LAYER COMPRISING ETHYLCELLULOSE OR A GASTRO-RESISTANT LAYER OR A LAYER COMPRISING ETHYLCELLULOSE IN TURN COATED WITH GASTRO-RESISTENT POLYMERS.THE FORMULATIONS OF THE INVENTION ARE PARTICULARLY SUITABLE TO OPTIMISE ABSORPTION, THE RILA-SHUE SITE AND THE EFFECT OF NUTRACEUTICALS WITH AN UNFAVOURABLE PROFILE IN TERMS OF “COMPLIANCE”, DUE TO A HIGH NUMBER OF DAILY ADMINISTRATION, AND COLLATERALI EFFECTS.SI IS FOUND THAT IT IS POSSIBLE TO EFFICIENTLY MODULATE THE ACTIVITY OF NUTRACEUTICAL PRODUCTS, REDUCING THE FREQUENCY OF THESE PRODUCTS (English) | |||||||||||||||
| Property / summary: THIS INVENTION CONCERNS CONTROLLED-RELEASE SOLID ORAL COMPOSITIONS COMPRISING A CORE CONSISTING OF A MONOLITHIC MATRIX COMPRISING AT LEAST ONE LOW, MEDIUM, AL-TA VISCOSITY HYDROXYPROPYLMETHYLCELLULOSE, OR A MIXTURE THEREOF, ANHYDROUS DICALCIUM PHOSPHATE OR MONOHYDRATE, METILCELLULOSE, ONE OR MORE SUPERDISGREGANT POLYMERS AND AN OUTER COATING OF THAT CORE CONSISTING OF A LAYER COMPRISING ETHYLCELLULOSE OR A GASTRO-RESISTANT LAYER OR A LAYER COMPRISING ETHYLCELLULOSE IN TURN COATED WITH GASTRO-RESISTENT POLYMERS.THE FORMULATIONS OF THE INVENTION ARE PARTICULARLY SUITABLE TO OPTIMISE ABSORPTION, THE RILA-SHUE SITE AND THE EFFECT OF NUTRACEUTICALS WITH AN UNFAVOURABLE PROFILE IN TERMS OF “COMPLIANCE”, DUE TO A HIGH NUMBER OF DAILY ADMINISTRATION, AND COLLATERALI EFFECTS.SI IS FOUND THAT IT IS POSSIBLE TO EFFICIENTLY MODULATE THE ACTIVITY OF NUTRACEUTICAL PRODUCTS, REDUCING THE FREQUENCY OF THESE PRODUCTS (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: THIS INVENTION CONCERNS CONTROLLED-RELEASE SOLID ORAL COMPOSITIONS COMPRISING A CORE CONSISTING OF A MONOLITHIC MATRIX COMPRISING AT LEAST ONE LOW, MEDIUM, AL-TA VISCOSITY HYDROXYPROPYLMETHYLCELLULOSE, OR A MIXTURE THEREOF, ANHYDROUS DICALCIUM PHOSPHATE OR MONOHYDRATE, METILCELLULOSE, ONE OR MORE SUPERDISGREGANT POLYMERS AND AN OUTER COATING OF THAT CORE CONSISTING OF A LAYER COMPRISING ETHYLCELLULOSE OR A GASTRO-RESISTANT LAYER OR A LAYER COMPRISING ETHYLCELLULOSE IN TURN COATED WITH GASTRO-RESISTENT POLYMERS.THE FORMULATIONS OF THE INVENTION ARE PARTICULARLY SUITABLE TO OPTIMISE ABSORPTION, THE RILA-SHUE SITE AND THE EFFECT OF NUTRACEUTICALS WITH AN UNFAVOURABLE PROFILE IN TERMS OF “COMPLIANCE”, DUE TO A HIGH NUMBER OF DAILY ADMINISTRATION, AND COLLATERALI EFFECTS.SI IS FOUND THAT IT IS POSSIBLE TO EFFICIENTLY MODULATE THE ACTIVITY OF NUTRACEUTICAL PRODUCTS, REDUCING THE FREQUENCY OF THESE PRODUCTS (English) / qualifier | |||||||||||||||
point in time: 1 February 2022
| |||||||||||||||
Revision as of 06:57, 1 February 2022
Project Q4209181 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | SOLID ORAL COMPOSITIONS (MONOLITHIC ARRAYS) |
Project Q4209181 in Italy |
Statements
3,600.0 Euro
0 references
7,200.0 Euro
0 references
50.0 percent
0 references
GIELLEPI S.P.A.
0 references
LA PRESENTE INVENZIONE HA PER OGGETTO COMPOSIZIONI ORALI SOLIDE A RILASCIO CONTROLLATO COMPRENDENTI UN CORE COSTITUITO DA UNA MATRICE MONOLITICA CHE COMPRENDE ALMENO UNA IDROSSIPROPILMETILCELLULOSA A BASSA, MEDIA, AL-TA VISCOSITà , OPPURE UNA LORO MISCELA, FOSFATO DICALCICO ANIDRO O MONOIDRATO, METILCELLULOSE, UNO O PIù POLIMERI SUPERDISGREGANTI E UN RIVESTIMENTO ESTERNO DI DETTO CORE COSTITUITO DA UNO STRATO COMPRENDENTE ETILCELLULOSA OPPURE DA UNO STRATO GASTRO-RESISTENTE OPPURE DA UNO STRATO COMPRENDENTE ETILCELLULOSA A SUA VOLTA RIVESTITO CON POLIMERI GASTRO-RESISTENTI.LE FORMULAZIONI DELL INVENZIONE RISULTANO PARTICOLARMENTE ADATTE PER OTTIMIZZARE L ASSORBIMENTO, IL SITO DI RILA-SCIO E L EFFETTO DI NUTRACEUTICI CON UN PROFILO SFAVOREVOLE IN TERMINI DI ÂCOMPLIANCEÂ, A CAUSA DI UN ELEVATO NU-MERO DI SOMMINISTRAZIONI GIORNALIERE, E DI EFFETTI COLLATERALI.SI Ê INFATTI TROVATO CHE Ê POSSIBILE MODULARE EFFICIENTEMENTE L ATTIVITà DEI PRODOTTI NUTRACEUTICI, RIDUCENDONE LA FREQUE (Italian)
0 references
THIS INVENTION CONCERNS CONTROLLED-RELEASE SOLID ORAL COMPOSITIONS COMPRISING A CORE CONSISTING OF A MONOLITHIC MATRIX COMPRISING AT LEAST ONE LOW, MEDIUM, AL-TA VISCOSITY HYDROXYPROPYLMETHYLCELLULOSE, OR A MIXTURE THEREOF, ANHYDROUS DICALCIUM PHOSPHATE OR MONOHYDRATE, METILCELLULOSE, ONE OR MORE SUPERDISGREGANT POLYMERS AND AN OUTER COATING OF THAT CORE CONSISTING OF A LAYER COMPRISING ETHYLCELLULOSE OR A GASTRO-RESISTANT LAYER OR A LAYER COMPRISING ETHYLCELLULOSE IN TURN COATED WITH GASTRO-RESISTENT POLYMERS.THE FORMULATIONS OF THE INVENTION ARE PARTICULARLY SUITABLE TO OPTIMISE ABSORPTION, THE RILA-SHUE SITE AND THE EFFECT OF NUTRACEUTICALS WITH AN UNFAVOURABLE PROFILE IN TERMS OF “COMPLIANCE”, DUE TO A HIGH NUMBER OF DAILY ADMINISTRATION, AND COLLATERALI EFFECTS.SI IS FOUND THAT IT IS POSSIBLE TO EFFICIENTLY MODULATE THE ACTIVITY OF NUTRACEUTICAL PRODUCTS, REDUCING THE FREQUENCY OF THESE PRODUCTS (English)
1 February 2022
0 references
MILANO
0 references